Short Interest in Biofrontera Inc. (NASDAQ:BFRI) Declines By 44.1%

Biofrontera Inc. (NASDAQ:BFRIGet Rating) was the recipient of a large decrease in short interest in the month of May. As of May 15th, there was short interest totalling 570,100 shares, a decrease of 44.1% from the April 30th total of 1,020,000 shares. Currently, 6.3% of the shares of the company are sold short. Based on an average trading volume of 1,810,000 shares, the short-interest ratio is currently 0.3 days.

NASDAQ BFRI opened at $2.94 on Friday. The stock’s fifty day moving average price is $3.43 and its 200 day moving average price is $4.22. Biofrontera has a 1 year low of $2.20 and a 1 year high of $14.63.

Biofrontera (NASDAQ:BFRIGet Rating) last posted its quarterly earnings results on Friday, April 8th. The company reported ($0.42) EPS for the quarter. The business had revenue of $9.17 million for the quarter. On average, analysts expect that Biofrontera will post -0.72 earnings per share for the current fiscal year.

Separately, Zacks Investment Research downgraded Biofrontera from a “hold” rating to a “sell” rating in a research report on Friday.

A number of large investors have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in Biofrontera in the fourth quarter valued at $76,000. Qube Research & Technologies Ltd purchased a new stake in shares of Biofrontera during the 4th quarter worth about $103,000. XTX Topco Ltd purchased a new stake in shares of Biofrontera during the 1st quarter worth about $48,000. State Street Corp purchased a new stake in shares of Biofrontera during the 1st quarter worth about $49,000. Finally, Geode Capital Management LLC purchased a new stake in shares of Biofrontera during the 4th quarter worth about $182,000. 4.10% of the stock is currently owned by institutional investors.

About Biofrontera (Get Rating)

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.

Further Reading

Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.